Episode
Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu
- Podcast
- RealTalk MS
- Published
- Feb 9, 2026
- Duration seconds
- 2009
- Processing state
not_requested- Canonical source
- https://realtalkms.com/441
Actions
POST https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-441-the-2026-actrims-forum-with-dr-manuel-friese-dr-amit-bar-or-and-dr-haritha-desu/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/realtalk-ms-779631/episode-441-the-2026-actrims-forum-with-dr-manuel-friese-dr-amit-bar-or-and-dr-haritha-desu.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the ACTRIMS Forum. This week, in Part One of our coverage, you'll hear from three of the experts who presented their research at the ACTRIMS Forum. Dr. Manuel Friese, a clinician-scientist at the Institute of Neuroimmunology and Multiple Sclerosis at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, where he serves as the Director of the Center for Molecular Neurobiology, and the Director of the Institute of Neuroimmunology and Multiple Sclerosis, is this year's winner of the Barancik Prize for Innovation in Multiple Sclerosis. I had an opportunity to talk with Dr. Friese about some of his truly remarkable research. Dr. Amit Bar-Or, the Director of the Centre for Neuroinflammation and Experimental Therapeutics (CNET) and Chief of the Division of Multiple Sclerosis (MS) and related disorders at the University of Pennsylvania, presented encouraging results from two important clinical trials. Dr. Bar-Or and I discussed what those results might mean for people living with relapsing-remitting and primary progressive MS. Dr. Haritha Desu, a young investigator at the ACTRIMS Forum, presented her cutting-edge research on how immune cells interact with cells already resident in the brain to drive damage or potentially promote repair. I talked with Dr. Desu about how her work could be key to stopping MS progression independent of relapse activity. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: The 2026 ACTRIMS Forum :22 Barancik Prize winner Dr. Manuel Friese discusses his pioneering discoveries 1:34 Dr. Amit Bar-Or shares encouraging results…